MiR‐22, a serum predictor of poor outcome and therapy response in diffuse large B‐cell lymphoma patients-Reference-Cited by-同舟云学术

MiR‐22, a serum predictor of poor outcome and therapy response in diffuse large B‐cell lymphoma patients

Published:2021-07-28 Issue:3 Volume:195 Page:399-404
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Rinaldi Federica¹,Marchesi Francesco²^ORCID,Palombi Francesca²,Pelosi Andrea³,Di Pace Anna Laura³,Sacconi Andrea⁴,Terrenato Irene⁴,Annibali Ombretta⁵,Tomarchio Valeria⁵,Marino Mirella⁶,Cantonetti Maria⁷,Vaccarini Sara⁷,Papa Elena²,Moretta Lorenzo³,Bertoni Francesco⁸⁹,Mengarelli Andrea²,Regazzo Giulia¹,Rizzo Maria G.¹^ORCID

Affiliation:

1. Department of Research, Advanced Diagnostics and Technological Innovation Oncogenomic and Epigenetic Unit Translational Research Area IRCCS Regina Elena National Cancer Institute RomeItaly

2. Department of Clinical and Experimental Oncology, Hematology and Stem Cell Transplant Unit IRCCS Regina Elena National Cancer Institute RomeItaly

3. Immunology Area Bambino Gesù Children’s Hospital IRCCS RomeItaly

4. Department of Research, Advanced Diagnostics and Technological Innovation Clinical Trial Center, Biostatistics and Bioinformatics Unit IRCCS Regina Elena National Cancer Institute RomeItaly

5. Hematology and Stem Cell Transplantation Unit University Campus Bio‐Medico RomeItaly

6. Department of Research, Advanced Diagnostics and Technological Innovation Pathology Unit IRCCS Regina Elena National Cancer Institute RomeItaly

7. Hematology Unit of Lymphoproliferative Disorders Policlinico Tor Vergata (PTV) Foundation Rome Italy

8. Faculty of Biomedical Sciences Institute of Oncology Research USI BellinzonaSwitzerland

9. Oncology Institute of Southern Switzerland Bellinzona Switzerland

Funder

H2020 Marie Skłodowska-Curie Actions

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17734

Reference19 articles.

1. Diffuse Large B-Cell Lymphoma

2. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

3. Diffuse large B-cell lymphoma genotyping on the liquid biopsy

4. Diffuse large B-cell lymphoma: Time to focus on circulating blood nucleic acids?

5. Exosome and Exosomal MicroRNA: Trafficking, Sorting, and Function

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Turning the tide in aggressive lymphoma: liquid biopsy for risk-adapted treatment strategies;Trends in Molecular Medicine;2024-07

2. Extracellular vesicles in cancer: challenges and opportunities for clinical laboratories;Critical Reviews in Clinical Laboratory Sciences;2024-02-15

3. Research advances in exosomal microRNAs associated with drug resistance in diffuse large B-cell lymphoma;Asian Journal of Surgery;2023-11

4. Exploring the cell-free total RNA transcriptome in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma patients as biomarker source in blood plasma liquid biopsies;Frontiers in Oncology;2023-10-25

5. Extracellular vesicles in hematological malignancies: EV-dence for reshaping the tumoral microenvironment;Frontiers in Immunology;2023-09-26